Coherus Biosciences | CHRS - Equity Capital And Reserves


Coherus Biosciences reported $60.84M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -4.58B 1.35B Sep/2026
Acadia Pharmaceuticals USD 1.39B 80.88M Sep/2026
Akebia Therapeutics USD 20.37M 4.65M Sep/2026
ALKERMES USD 1.86B 56.17M Sep/2026
Alnylam Pharmaceuticals USD 3.6B 2.25B Sep/2026
Amarin USD 444.41M 796K Sep/2026
Amgen USD 14.35B 2.66B Sep/2026
Baxter International USD 6.5B 296M Sep/2026
Biogen USD 19.04B 194.3M Sep/2026
BioMarin Pharmaceutical USD 6.26B 65.66M Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Coherus Biosciences USD 60.84M 17.78M Jun/2026
Eli Lilly USD 40.27B 6.39B Sep/2026
Fujifilm JPY 3.82T 82.7B Sep/2026
Gilead Sciences USD 13.04B 1.3B Sep/2026
Ironwood Pharmaceuticals USD -97.19M 64.65M Sep/2026
Merck USD 44.89B 2.96B Sep/2026
Myriad Genetics USD 303.9M 33.5M Jun/2026
Pacira USD 712.32M 40.34M Sep/2026
Perrigo USD 2.44B 75.4M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
PTC Therapeutics USD -191.21M 25.85M Sep/2026
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Sarepta Therapeutics USD 1.53B 1.06M Sep/2026
Teva Pharmaceutical Industries USD 7.98B 226M Sep/2026
Vertex Pharmaceuticals USD 20.91B 659.5M Sep/2026
Xencor USD 560.43M 57.21M Sep/2026
Zoetis USD 3.3B 155M Sep/2026